MPO and rheumatoid arthritis: Many reports documented that TNFi (i.e., etanercept and infliximab) have positive effects on the oxidant damage of RA, promoting reduction in serum and urinary levels of oxidative DNA damage, myeloperoxidase activity, and lipid peroxidation, in parallel to an equivalent decrease in DAS28 [67].